Atreca to Present at Upcoming Investor Conferences
Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company, announced its upcoming presentations at major investor conferences. The schedule includes:
- H.C. Wainwright Global Investment Conference: May 25, 2022, at 8:30 am EDT
- Cowen’s 3rd Annual Oncology IO Next Summit: June 2, 2022, at 2:00 pm EDT
- Jefferies Healthcare Conference: June 9, 2022, at 9:00 am EDT
Live webcasts will be available on their website, with replays accessible for 30 days post-event.
- None.
- None.
SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming investor conferences:
H.C. Wainwright Global Investment Conference
May 23-26, 2022
Presentation: 8:30 am EDT, May 25, 2022
Cowen’s 3rd Annual Oncology IO Next Summit
June 2, 2022
Presentation: 2:00 pm EDT, June 2, 2022
Jefferies Healthcare Conference
June 8-10, 2022
Fireside Chat: 9:00 am EDT, June 9, 2022
A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at http://ir.atreca.com. An archived replay will be available on the Company's website for 30 days following each event.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, a monoclonal antibody targeting a novel RNP complex, and ATRC-301, an ADC targeting a novel epitope on EphA2. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients, and ATRC-301 is in IND-enabling studies. For more information on Atreca, please visit www.atreca.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, ATRC-301, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com
Investors:
Alex Gray, 650-779-9251
agray@atreca.com
Media:
Julia Fuller, 858-692-2001
julia@fordhutmanmedia.com
Source: Atreca, Inc.
FAQ
What events is Atreca presenting at in May and June 2022?
What time is Atreca's presentation at the H.C. Wainwright Global Investment Conference?
Where can I access Atreca's conference presentations?
What is the stock symbol for Atreca?
What is the focus of Atreca as a biotechnology company?
